Shermineh Farmand1, Jonatan D Lindh2, Jan Calissendorff3, Jakob Skov4, Henrik Falhammar3, David Nathanson1, Buster Mannheimer5. 1. Department of Clinical Science and Education at Södersjukhuset, Karolinska University Hospital, Stockholm, Sweden. 2. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Clinical Science and Education at Södersjukhuset, Karolinska University Hospital, Stockholm, Sweden. Electronic address: buster.mannheimer@sll.se.
Abstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are important as a cause of hyponatremia. However, most studies have focused on the effect on sodium levels regardless of clinical symptoms, or have been too small to be able to discriminate between the effects of specific antidepressant drugs. The objective of the present study was to investigate the association between different groups of antidepressants and the risk of hospitalization due to hyponatremia. METHODS: In this register-based case-control study of patients in the general Swedish population, we identified 14,359 individuals with a main diagnosis of hyponatremia. For every case, 4 matched controls were included (n = 57,382). To investigate the temporal aspects of drug-induced hyponatremia, antidepressant exposure was divided into patients with newly initiated and ongoing treatment. Univariable and multivariable logistic regression was used to analyze the association of antidepressant use and hospitalization. RESULTS: For newly initiated antidepressants, adjusted odds ratios (95% confidence interval) for a main diagnosis of hyponatremia compared with controls were: citalopram 5.50 (4.71-6.44); sertraline 4.96 (3.81-6.48); venlafaxine 5.28 (3.20-8.83); tricyclic antidepressants 1.59 (1.13-2.24); and mirtazapine 2.54 (2.04-3.16). Adjusted odds ratio (confidence interval) for individuals with ongoing treatment ranged from 0.57 (0.52-0.63) for citalopram to 1.08 (0.85-1.36) for other SSRIs. CONCLUSIONS: There was a strong association between newly initiated treatment with SSRIs or venlafaxine and hospitalization due to hyponatremia. The association for tricyclic antidepressants and mirtazapine was small to moderate. In contrast, there was no evidence that ongoing treatment with antidepressants increases the risk for hospitalization due to hyponatremia. Crown
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are important as a cause of hyponatremia. However, most studies have focused on the effect on sodium levels regardless of clinical symptoms, or have been too small to be able to discriminate between the effects of specific antidepressant drugs. The objective of the present study was to investigate the association between different groups of antidepressants and the risk of hospitalization due to hyponatremia. METHODS: In this register-based case-control study of patients in the general Swedish population, we identified 14,359 individuals with a main diagnosis of hyponatremia. For every case, 4 matched controls were included (n = 57,382). To investigate the temporal aspects of drug-induced hyponatremia, antidepressant exposure was divided into patients with newly initiated and ongoing treatment. Univariable and multivariable logistic regression was used to analyze the association of antidepressant use and hospitalization. RESULTS: For newly initiated antidepressants, adjusted odds ratios (95% confidence interval) for a main diagnosis of hyponatremia compared with controls were: citalopram 5.50 (4.71-6.44); sertraline 4.96 (3.81-6.48); venlafaxine 5.28 (3.20-8.83); tricyclic antidepressants 1.59 (1.13-2.24); and mirtazapine 2.54 (2.04-3.16). Adjusted odds ratio (confidence interval) for individuals with ongoing treatment ranged from 0.57 (0.52-0.63) for citalopram to 1.08 (0.85-1.36) for other SSRIs. CONCLUSIONS: There was a strong association between newly initiated treatment with SSRIs or venlafaxine and hospitalization due to hyponatremia. The association for tricyclic antidepressants and mirtazapine was small to moderate. In contrast, there was no evidence that ongoing treatment with antidepressants increases the risk for hospitalization due to hyponatremia. Crown
Authors: Hans Järnbert-Pettersson; Marine L Andersson; Katarina Bilén; Olle Broström; Jonatan D Lindh; Buster Mannheimer Journal: PLoS One Date: 2019-04-17 Impact factor: 3.240
Authors: Jonatan D Lindh; David Nathanson; Buster Mannheimer; Jakob Skov; Henrik Falhammar; Jan Calissendorff Journal: Endocrine Date: 2019-09-02 Impact factor: 3.633
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; Jonatan D Lindh; Buster Mannheimer Journal: J Psychopharmacol Date: 2020-07-20 Impact factor: 4.153
Authors: Andrea Christine Shysh; Zahinoor Ismail; Davinder Sidhu; Maggie Guo; Leonard T Nguyen; Christopher Naugler Journal: Drugs Real World Outcomes Date: 2021-05-23
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; David Nathanson; Jonatan D Lindh; Buster Mannheimer Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958
Authors: Buster Mannheimer; Henrik Falhammar; Jan Calissendorff; Jakob Skov; Jonatan D Lindh Journal: J Psychopharmacol Date: 2021-04-16 Impact factor: 4.153
Authors: Johanna Seifert; Martin Letmaier; Timo Greiner; Michael Schneider; Maximilian Deest; Christian K Eberlein; Stefan Bleich; Renate Grohmann; Sermin Toto Journal: J Neural Transm (Vienna) Date: 2021-07-01 Impact factor: 3.575